Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has been a serious obstacle in front of public health. Interferon-beta 1a (IFN-β 1a) has been used to treat patients with COVID-19. We aimed to compare the effectiveness of high-dose IFN-β 1a compared to low dose IFN-β 1a in severe COVID-19 cases.
Methods: In this randomized, controlled, and clinical trial, eligible patients with confirmed SARS-CoV-2 infections were randomly assigned to receive one of the two following therapeutic regimens: The intervention group was treated with high-dose IFN-β 1a (Recigen) (Subcutaneous injections of 88 μg (24 million IU) on days 1, 3, 6) + lopinavir /ritonavir (Kaletra) (400 mg/100 mg twice a day for 10 days, orally) and the control group was treated with low-dose IFN-β 1a (Recigen) (Subcutaneous injections of 44 μg (12 million IU) on days 1, 3, 6) + lopinavir /ritonavir (Kaletra) (400 mg/100 mg twice a day for 10 days, orally).
Result: A total of 168 COVID- 19 confirmed patients underwent randomization; 83 were assigned to the intervention group and 85 were assigned to the control group. Median Time To Clinical Improvement (TTIC) for cases treated with low-dose IFN-β1a was shorter than that for cases treated with high-dose IFN-β1a (6 vs 10 days; P = 0.018). The mortality rates in intervention and control group were 41% and 36.5%, respectively.
Conclusion: The use of high-dose IFN-β 1a did not improve TTCI in hospitalized patients with moderate to severe COVID-19. Also, it did not have any significant effect on mortality reduction compared with treating with low-dose IFN-β 1a.
Trial registration: This trial has been registered as ClinicalTrials.gov, NCT04521400 .
Keywords: COVID-19; Interferon-β 1a; Lopinavir/ritonavir; Randomized controlled trial; SARS-COV-2.
【저자키워드】 COVID-19, Randomized controlled trial, SARS-CoV-2, Lopinavir/ritonavir, Interferon-β 1a, 【초록키워드】 Randomized controlled trial, coronavirus disease, public health, Coronavirus disease 2019, clinical trial, Lopinavir/ritonavir, Mortality, Trial, randomization, severe COVID-19, SARS-COV-2 infection, Lopinavir, Ritonavir, interferon, Intervention, hospitalized patients, COVID, improvement, Randomized, clinical, low-dose, low dose, therapeutic, Patient, Effectiveness, Clinical improvement, Interferon-beta, mortality rate, mortality rates, moderate, SARS-CoV-2 infections, Kaletra, moderate to severe, twice a day, reduction, High-dose, Subcutaneous, subcutaneous injections, control group, intervention group, significant effect, Eligible patients, median time, IFN-β, TTCI, Registered, injection, treat, time, Randomly, Recigen, TTIC, IMPROVE, treated, hospitalized patient, assigned, receive, eligible patient, patients with COVID-19, 【제목키워드】 interferon beta, High-dose, Effect, The COVIFERON,